
Opinion|Videos|March 6, 2025
Comparing Approved ADC Options in HER2-Negative and HER2-Low Breast Cancer
Panelists discuss how antibody-drug conjugates (ADCs) for breast cancer (BC) differ in their safety profiles, with trastuzumab deruxtecan (T-DXd) having notable interstitial lung disease risk, sacituzumab govitecan (SG) associated with neutropenia/diarrhea, and datopotamab deruxtecan (Dato-DXd) showing a relatively favorable safety profile but still requiring monitoring.
Advertisement
Episodes in this series

Video content above has been prompted by the following:
- Could you walk through the ADC therapies that are approved for HR+ HER2-negative/low and triple-negative BC?
- What key differences in the safety of T-DXd, SG, and Dato-DXd are important for pharmacists to understand?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
2
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
3
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
4
Closing the Gaps in Men’s Health Through MTM and Community Engagement
5




















































































































